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Abstract
Exosomes are nanoscale extracellular membrane vesicles that are created by the fusion of an intracellular multivesicular
body with the cell membrane. They are widely distributed in serum, urine, saliva and other biological fluids. As important
transfer vectors for intercellular communication and genetic material, exosomes can stimulate target cells directly via
receptor-mediated interactions or via the transfer of various bioactive molecules, such as cell membrane receptors, proteins,
mRNAs and microRNAs, thus exerting their biological functions. This review focuses on the biological characteristics of
exosomes, as well as their role and underlying mechanisms of action in the evolution of tumor formation, metastasis, drug
resistance and other malignant behaviors. Additionally, this review emphasizes the potential applications of exosomes in the
treatment of tumors. Further research may provide new ideas and methods to establish effective, exosome-based strategies
for the early diagnosis and treatment of tumors.
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Background
In 1981, when Trams et al. studied vesicles in normal
and tumor cells, they unexpectedly dicovered another
group of vesicle-like substance which were smaller than
multivesicular under transmission electron microscope
[1]. Then, in 1987, Johnstone et al. named this kind of
membrane vesicles as “exosomes”, and meanwhile, they
observed exosome formation during reticulocyte matur-
ation and successfully isolated and purified exosomes
from reticulocytes by centrifugation at 100,000 x g for
90 min for the first time [2]. In 1996, Raposo et al. [3]
found that in human B lymphocytes, some membrane
vesicles isolated by differential centrifugation possessed
the ability to present antigens. They expressed abundant
major histocompatibility complex (MHC) II molecules
on their surface and could present antigens to T cells,
leading to T cell activation. Then, researchers found that
except for within living cells, exosomes can also be de-
tected in vitro in the cultures of different cell types, such
as dendritic cells (DCs), epithelial cells, platelets, mesen-
chymal stem cells (MSCs), and tumor cells [4–8].
Exosomes are widely present in all body fluids, including
saliva, blood, urine, cerebrospinal fluid, pleural effusion
and ascites, suggesting that exosomes are not limited to
the metabolic products of normal physiological and
pathological conditions and that the secretion of exo-
somes is a universal cellular function [9]. Exosomes have
been found to participate in many important physio-
logical functions as the transmission medium for inter-
cellular communication. Exosomes are involved in the
regulation of the immune response, inflammation and
tumor development [10–12]. In this review, we will con-
duct an in-depth discussion on not only the biological
characteristics of exosomes and their relationship with
tumors but also their potential clinical applications.
Biological characteristics of exosomes
Generation of exosomes
Exosomes are vesicle-like bodies that are secreted by
cells and are 40 ~ 100 nm in diameter. As viewed by
electron microscopy, exosomes are encompassed by a bi-
layer of phospholipid molecules, are cup- or plate-like in
shape, and are usually enriched in a 1.13 ~ 1.19 g/ml su-
crose density gradient solution [13]. Exosome synthesis
and secretion involves a series of complex biological
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processes. First, a particular part of the cell membrane
retracts, buds and forms an early endosome. Then,
under the regulation of endocytosis-associated proteins
and lipid raft complexes, early endosomes transform into
late endosomes contained by intraluminal vesicles, i.e.,
multivesicular bodies (MVBs). At the same time, during
the process of Ca2+-dependent ubiquitination and nu-
cleic acid separation, some cytoplasmic proteins and nu-
cleic acids become localized in MVBs [14, 15]. Finally,
the MVBs that are not degraded by lysosomes will inte-
grate and dock with the cell membrane with the partici-
pation of the Ras superfamily GTPase Rab; then, the
MVBs release their contents into the extracellular space,
creating exosomes [15]. In this process, some factors,
such as platelet activation, radical pressure, decreased
membrane cholesterol content and increased intracellu-
lar calcium levels, can increase the number of exosomes
produced (Fig. 1).
Molecular composition of exosomes
As potential biological material transporters, exosomes
are usually composed of a series of biomolecules, includ-
ing proteins, short-chain peptides, lipids, and fragments
of DNA, mRNA, and microRNA (miRNA). The compo-
nents of exosomes are closely related to the source and
pathophysiological state of the secretory cells [16].
Based on traditional methods, such as SDS-PAGE and
proteomic analysis, the proteins of exosomes have been
mainly divided into two types, one of which includes
common proteins distributed in every exosome, such as
transmembrane transport and integration-related pro-
teins (e.g., G protein, annexin, flotillin), tetraspanins
(CD9, CD63, CD81, CD82) and heat shock proteins
(Hsp70, Hsp90) [17, 18]. In particular, CD9 and CD63
are often used as molecular markers of exosomes that
can be identified from a variety of extracellular vesicle-
like structures, such as MVBs or apoptotic bodies; how-
ever, exosome-specific proteins have yet to be discovered
[19]. The other protein type includes proteins that exist
in specific types of exosomes; for example, MHC and
costimulatory CD80 or CD86 molecules are abundant in
exosomes surface originating from DCs and B lympho-
cytes, and a number of tumor antigens are contained in
tumor cell-derived exosomes [20].
In addition to proteins, exosomes are also rich in
lipids. The lipid components of exosomes are different
from those of the cell membrane. Compared to their
parent cells, exosomes is consist of phosphatidylserine,
double-unsaturated phosphatidylethanolamine, double-
unsaturated phosphatidylcholine, sphingomyelin, ganglia
glycoside GM3, and cholesterol [16]. This unique com-
bination is beneficial not only for maintaining high exo-
some stability but also for facilitating uptake by recipient
cells.
Furthermore, exosomes contain a variety of non-
coding RNAs or fragments, including overlapping
protein-coding region RNA transcripts, repeats, struc-
tural RNAs, fragments of transfer RNAs, short hairpin
RNAs, Y RNAs and small interfering RNAs (siRNAs)
[21]. RNAs isolated from exosomes are more enriched
Fig. 1 Biogenesis, release and upstake of exosomes
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than those in parental cells, which further demonstrates
the selectivity of RNA incorporation into exosomes
[22–24]. Many studies have detected abnormal
miRNA expression in exosomes isolated from the
body fluids of patients with various types of cancer,
suggesting that miRNAs have potential as diagnostic
and prognostic biomarkers [25–45] (Table 1).
These components (e.g., proteins, mRNA and miRNA)
can be selectively incorporated into the exosomes [46].
However, the exact molecular events that regulates the
packaging of exosomes either via vesicle-mediated or
non-vesicle-mediated mechanisms are largely unclear.
Source and isolation of exosomes
A variety of cell types have been used to produce exo-
somes in cancer research. In particular, immature den-
dritic cells (imDCs) have become one of the most
popular donor cells due to their unique surface proteins
[47]. CD9 on imDC-derived exosomes can promote the
fusion of exosomes with the membrane of target cells,
thus increasing the delivery of drugs [48]. Furthermore,
exosomes derived from imDCs lack immunostimulatory
T cell surface markers, such as CD40, CD86, and MHC
II, and thus have reduced immunogenicity [20]. There-
fore, they can effectively induce defensive immune
responses after being loaded with tumor antigens. A
clinical trial on pancreatic cancer has confirmed the
safety of imDC-derived exosomes [49]. However, the
clinical application of imDC-derived exosomes is limited
by small-scale production. MSCs are often used as exo-
some donor cells in glioma-related studies [50]. Due to
their considerable production of exosomes, MSCs have
potential as an effective source of exosomes for clinical
applications. However, the anti-tumor effect of MSC-
derived exosomes remains controversial [51, 52]. There-
fore, the selection of exosome donor cells must take
both tissue-specific targets and yield into consideration.
Considering the crucial role of exosomes in biological
and clinical research, the methods by which exosomes
are isolated from donor cells are very important. How-
ever, the unique size and structure of exosomes make
their isolation and purification difficult. Frequently used
methods include ultracentrifugation, ultrafiltration, dens-
ity gradient centrifugation, precipitation polymerization,
and magnetic-activated cell sorting. The differences of
these five methods and assessments of their efficiency and
Table 1 Exosomal miRNAs isolated from body fluids of cancer patients as potential biomarkers
Cancer type Biofluid Relevant miRNA Reference
Lung cancer Plasma miR-151a-5p, miR-30a-3p, miR-200b-5p,
miR-629, miR-100, miR-154-3p
[26]
Plasma let-7f, miR-30e-3p, miR-223, miR-301 [27]
Plasma miR-17-3p, miR-21, miR-106a, miR-146,
miR-155 miR-191, miR-192, miR-203,
miR-205, miR-210, miR-212, miR-214
[28]
Nasopharyngeal carcinoma Serum miR-24-3p, miR-891a, miR-106a-5p,
miR-20a-5p, miR-1908
[29]
Esophageal Serum miR-21 [30]
squamous cell carcinoma Serum miR-1246 [31]
Breast cancer Serum miR-200a, miR-200c, miR-205 [32]
Serum miR-21 [33]
Serum miR-101, 372, 373 [34]
Hepatocellular carcinoma Serum miR-21 [35]
Pancreatic cancer Serum miR-17-5p, miR-21 [36]
Serum miR-1246, miR-4644, miR-3976, miR-4306 [37]
Prostate cancer Plasma, Serum, miR-107, miR-141, miR-375, miR-574-3p [38]
Urine, Serum miR-141 [39]
Glioblastoma Serum miR-320, miR-574-3p [40]
Cerebrospinal fluid miR-21 [41]
Colorectal cancer Serum Let-7a, miR-1229, miR-1246, miR-150,
miR-21, miR-223, miR-23a
[42]
Serum miR-17-92a cluster [43]
Ovarian cancer Serum miR-21, miR-141, miR-200a, miR-200b,
miR-200c, miR-203, miR-205, miR-214
[44]
Cervical cancer Cervicovaginal lavage miR-21, miR-146a [45]
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cost are shown in Fig. 2 [53]. As each of these methods
has advantages and disadvantages, so it is necessary to de-
velop more efficient extraction methods.
Tumor promotion role of exosomes
Exosomes and tumor proliferation
In prostate cancer, glioblastoma, breast cancer and other
tumors, exosomes have been confirmed to be closely
associated with tumor cell proliferation [54–56]. The
underlying mechanisms can potentially be used as tar-
gets for cancer therapeutics.
Exosomes affect heterogeneous cells in the microenvir-
onment by transferring a cancerous phenotype and indu-
cing cells to undergo malignant transformation; thus,
exosomes play an important role in cancer progression.
For example, exosomes in the serum of breast cancer
patients were injected into mice together with normal
epithelial cells and ultimately induced the formation of
tumors in mice, while exosomes derived from normal
subjects did not have this capability [57]. Exosomes se-
creted from prostate cancer cells are able to transform
adipose stem cells into cancer cells possibly induced by
their cargo of proteins, mRNA and miRNAs [58]. Bone
marrow-derived MSCs from patients with multiple mye-
loma contain high levels of cytokines and adhesion mol-
ecules, which can promote the growth of multiple
myeloma cells and contribute to the infiltration of can-
cer cells into the surrounding stromal tissue [59]. Pros-
tate cancer cell-derived exosomes can increase the
proliferation of LNCaP and RWPE cells and inhibit
aging; exosomes derived from another prostate cancer
cell line, DU145, can increase the volume of xenograft
tumors and enhance the serum levels of prostate specific
antigen [54]. Thus, exosomes derived from malignant tu-
mors have the ability to induce carcinogenesis or trans-
formation in normal cells.
In addition, the increased number of tumor cells is
closely related to elevated cell viability and decreased
apoptosis and necrosis. The contents of exosomes are
rich, and many of these materials can modulate the viabil-
ity and apoptotic ability of recipient cells. Upon entering
recipient cells, these materials activate proliferation-
related gene products of the recipient cells, leading to
changes in cellular behavior and an increase in tumor vol-
ume. Yang et al. [60] demonstrated that bladder cancer
cell-derived exosomes have the ability to inhibit tumor cell
Fig. 2 Approaches for exosome isolation. General procedures and assessment of the five commonly used approaches are shown
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apoptosis, thus promoting tumor progression. As such,
inhibiting the formation and release of exosomes from
bladder cancer cells could lead to new strategies for future
bladder cancer treatments. Caspase-3 can induce cell
apoptosis. Upon the inhibition of exosome release, caspase-
3 will accumulate, leading to apoptosis [60]. Thus, tumor
cells might inhibit caspase-3 accumulation by releasing exo-
somes containing caspase-3, thereby avoiding apoptosis.
Similarly, liver cancer cell-derived exosomes can
transfer the highly conserved long non-coding RNA
ucRNATUC339 to liver cancer cells, thereby promot-
ing cell proliferation; the use of siRNA to inhibit the
expression of TUC339 can reduce the proliferation of
hepatocellular carcinoma (HCC) cells [61].
Exosomes and tumor metastasis
The epithelial-to-mesenchymal transition (EMT) is a
highly conserved biological process by which cells lose
epithelial and gain mesenchymal characteristics, includ-
ing changes in cell morphology and phenotype. This
process is the initial step in tumor cell invasion and dis-
tant metastasis [62]. Josson et al. [63] demonstrated via
morphological and biochemical findings that after stro-
mal cell-derived exosomes transport of miRNAs into
tumor cells, the tumor cells will undergo the EMT. Fur-
thermore, many proteins found within exosomes are in-
volved in the induction of the EMT, including
transforming growth factor (TGF)-β, tumor necrosis
factor-α, interleukin (IL)-6, tumor susceptibility gene
101, Akt, integrin-linked kinase 1, β-catenin, and matrix
metalloproteinases [64, 65]. Functional studies have
shown that exosomes use these bioactive components to
induce the formation of a pro-metastatic phenotype in
recipient cells. After the occurrence of the EMT, tumor
cells have enhanced invasion and metastasis capabilities
and a high level of malignancy, leading to a significantly
worse prognosis [66].
In addition, exosomes may also mediate the transfer of
metastasis-related substances between cells to confer
those cells with the characteristic features necessary for
distant metastasis [67]. CD44v6 overexpression in rat
pancreatic carcinoma cells can induce a strong meta-
static ability [68]. Jung et al. and Wang et al. [69, 70] re-
ported that rat pancreatic cancer cell-derived exosomes
loaded with CD44v6 might promote the formation of
environments supporting tumor metastasis in rat lymph
nodes and lungs and that CD44v6 is a potential bio-
marker for cells initiating pancreatic adenocarcinoma.
Crossing the blood-brain barrier is a key step in the me-
tastasis of tumor cells to the brain. Tominaga et al. [71]
demonstrated that tumor cell-derived exosomes were in-
volved in the destruction of the blood-brain barrier and
thereby promoted tumor cell metastasis to the brain.
Moreover, exosomes released by tumor cells can also
change the physiological status of both the surrounding
tissue and distant cells, indirectly contributing to the
growth and spread of cancer cells, e.g., by stimulating
vascular permeability or adjusting the local environment
of organs before metastasis occurs [72, 73]. For example,
tumor cells can secrete exosomes with high levels of
miR-122, which can inhibit glucose absorbance in non-
cancerous cells before metastasis, thereby increasing the
available energy supply at distant organ microniches
(niches) and ultimately promoting disease development
[74]. Thus, during the formation of pre-metastasis mi-
croenvironments, exosomes play a relatively obscure but
crucial role. Exosomes released by highly invasive melan-
oma cells can remodel bone marrow precursor cells into
vessel-like cells to increase the degree of primary cancer
malignancy [75]. Pancreatic cancer cell-derived exo-
somes carrying macrophage migration inhibitory factor
can induce Kupffer cells to secrete TGF-β, resulting in
hepatic stellate cell activation and extracellular matrix
remodeling. Such reprogramming of the microenviron-
ment significantly promotes the infiltration of bone
marrow-derived macrophages, which provide a favorable
microniche for pancreatic cancer cells to metastasize to
the liver [73].
Recent studies have found that tumor cell-derived exo-
somes can promote the metastasis of tumor cells
through integrins. Additionally, the type of integrin can
determine the metastatic direction of a malignant tumor,
i.e., before primary tumor metastasis, released exosomes
are first transferred to the target organ to prepare the
environment for tumor cell colonization and facilitate
metastasis [8]. Hoshino et al. [12] found that the integral
proteins of exosomes derived from various types of
tumor cells widely vary; integrins α6β4 and α6β1 play a
key role in lung metastasis, and integrin αvβ5 plays a
role in hepatic metastasis. After exosomes carrying
integrins are absorbed, the adhesion ability of recipient
cells will be enhanced, Src phosphorylation will be acti-
vated, and the expression of the proinflammatory gene
S100 will be upregulated, thereby promoting tumor me-
tastasis. These findings provide a new direction for the
development of integrin-targeted anti-tumor drugs.
Exosomes and angiogenesis
Tumor angiogenesis is the key to tumor growth, invasion
and metastasis because new blood vessels can supply oxy-
gen and other nutrients to tumor cells. Angiogenesis can
usually be attributed to the pre-vascular angiogenic factors
secreted by various cells in the microenvironment, such as
vascular endothelial growth factor (VEGF), which stimu-
lates neighboring endothelial cells to recruit mast cells
and macrophages from the bone marrow [76]. However,
exosomes are often involved in this process. Exosomes
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containing EGFRvIII that are released from tumor cells
can induce autocrine VEGF signaling in endothelial cells,
thus leading to VEGFR activation and subsequent neovas-
cularization [77]. Proteins and/or mRNAs isolated from
highly malignant glioblastoma multiforme (GBM) cells in
patient plasma reflect the tumor-associated hypoxia status
and invasion characteristics. In addition, under hypoxic
conditions, exosomes released by GBM cells can induce
the synthesis of factors that can stimulate the activation of
the phosphoinositide 3-kinase/Akt signaling pathway or
accelerate angiogenesis, among other tumor growth-
related processes [78]. Similarly, tissue factor (TF) in colo-
rectal cancer cells can directly connect the genetic state of
cells (such as K-ras oncogene activation or the functional
loss of the p53 tumor suppressor gene) with their angio-
genic and proliferative abilities in vivo. Interestingly, exo-
somes containing TF can modulate angiogenesis and
stimulate tumor growth in vivo, although they cannot
promote the proliferation of cancer cells in vitro [79].
Furthermore, in the process of tumor angiogenesis, myofi-
broblasts in the tumor microenvironment also play an im-
portant role. Webber et al. [80] found that prostate cancer
and mesothelioma cells release exosomes containing
TGF-β, which acts on recipient cells and induces the dif-
ferentiation of fibroblasts into myofibroblasts. Cho et al.
[81] reported that after exosomes secreted by breast can-
cer cells were taken up by adipose tissue-derived MSCs,
the SMAD signaling pathway was activated and myofibro-
blast differentiation began. Thus, exosomes released by
tumor cells can recruit fibroblasts and induce fibroblast
differentiation, leading to tumor angiogenesis.
Exosomes and tumor immunity
Exosomes play different roles in the regulation of the
immune system due to their different contents. Some
exosomes have a strong inhibitory effect on the immune
system, and the mechanism of action is involved with
many aspects of the immune system.
Exosomes can promote the immunosuppressive effect
of regulator T cells (Tregs) to inhibit the natural anti-
tumor immune response. Studies have shown that exo-
somes derived from head and neck squamous cell
carcinoma PCI-13 cells can induce Treg proliferation
and differentiation and increase the expression of TGF-β
[82]. Szajnik et al. [83] found that exosomes from the
serum of patients with stage Шc ovarian cancer, fallopian
tube cancer or primary peritoneal cancer also mediate
the transformation of CD4+CD25neg T cells into CD4
+CD25highFoxp3+ Tregs, increase the expression of IL-
10, TGF-1, FasL, cytotoxic T lymphocyte-associated
antigen-4, perforin and granzyme B, and enhance STAT3
phosphorylation. In addition, Mrizak et al. [84] reported
that exosomes carrying TGF-β protein could induce
Treg amplification in nasopharyngeal carcinoma. Thus,
as exosomes play an important role in Treg amplifica-
tion, blocking exosome-mediated Treg amplification
could serve as a tumor immunotherapy strategy.
Some exosomes can also pass the death signal via
FasL, thus causing the apoptosis of T cells and exerting
immunosuppressive effects. For example, exosomes de-
rived from the ascites of patients with advanced ovarian
cancer were found to have high expression levels of
FasL, which inhibited the expression of CD3 and JAK3
and induced T cell apoptosis [85]. Colon cancer cell-
derived exosomes expressing FasL can also cause the
apoptosis of Fas-sensitive T cells, and this effect can be
blocked by anti-FasL antibodies [86, 87].
In addition, Cereghetti et al. [88] reported that exo-
somes derived from HCC1806 breast cancer cells con-
tained hsa-miR-146a, miR-29a and miR-21, as well as
many other miRNAs related to lymphocyte development
and function. These exosomes thus inhibited the devel-
opment and activation of lymphocytes and were involved
in the adaptive immune response. TW03 nasopharyngeal
carcinoma cell-derived exosomes can inhibit the prolifer-
ation and differentiation of Th1 cells and Th17 cells,
promote Treg differentiation, and suppress the immune
response [26].
Exosomes derived from the TS/A tumor cells can
down-regulate the expression of NKG2D and lead to
the secretion of perforin via TGF-β, MHC I-related
chain A/B and UL16 binding protein-3, thus inhibit-
ing natural killer (NK) cell function as well as the
innate immune response [89, 90].
Exosomes may also mediate M2 macrophage amplifi-
cation locally at tumor sites. Meghan et al. [91] demon-
strated that exosomes derived from myeloid-derived
suppressor cells can cause M2 macrophage polarization
by inhibiting the secretion of IL-12 by macrophages,
which in turn inhibits T cell function.
Exosomes and tumor resistance
Tumor cell resistance is the main reason for the failure
of clinical tumor treatment, which limits the clinical ap-
plication of chemotherapy drugs. Overcoming drug re-
sistance has become essential for achieving clinical
efficacy.
As a newly discovered means of intercellular commu-
nication, exosomes can transmit distinct signals (includ-
ing those of cellular drug resistance activity) among cells
via drug efflux, which is a potential mechanism related
to tumor resistance. Early clinical studies have suggested
that exosomes can mediate the transfer of resistance
from docetaxel-resistant prostate cancer cells to non-
resistant cells, which is accompanied by changes in cell
proliferation and invasiveness [92]. Additionally, exo-
somes released by cisplatin-resistant ovarian cancer cells
contained not only cisplatin but also the drug transport
Xu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:156 Page 6 of 12
protein ATP-binding cassette, subfamily C, member 2
and ATPase copper transporting alpha and beta, the lat-
ter of which activate signaling pathways in recipient
cells, eventually reducing the sensitivity of the originally
drug-sensitive cancer cells [93]. In breast cancer cell
lines, tumor cells are not only able to pass a key
molecule that mediates multidrug resistance, i.e.,
P-glycoprotein (P-gp), conferring the recipient cells with
multidrug resistance, but also can regulate the expres-
sion level of P-gp by passing miRNA in order to enhance
congenital resistance [94–96].
Cross-talk between stromal cells and cancer cells is
also important for driving the resistance of breast cancer
cells to chemotherapy and radiation therapy. During ex-
changes among heterogeneous cells, exosomes will be
transferred from stromal cells to breast cancer cells. The
RNAs within the exosomes are mostly non-coding tran-
scripts and transposable elements, which can stimulate
pattern recognition receptors and roundabout guidance
receptors, thus activating STAT-dependent signaling
[97]. In this way, stromal cells can activate the Notch3
pathway in breast cancer cells; then, stromal cells can re-
lease exosomes to coordinate with Notch3, thus promot-
ing the proliferation of those resistant cancer cells [98].
Therefore, in the development of tumor resistance, cancer
cells and surrounding stromal cells in the microenviron-
ment can have a significant and far-reaching impact.
Exosomes and tumor therapy
Exosomes as transport carriers for targeted cancer
therapeutics
As exosomes enable the exchange of information among
tumor cells, the specific nucleic acids and proteins they
carry can provide new targets for the treatment of can-
cer. Compared with conventional materials used for tar-
geted biological therapies, exosomes have many
advantages. 1) The large number of proteins and the
genetic information contained within exosomes suggest
that exosomes can be loaded with most biological sub-
stances. 2) Exosomes are widely distributed in various
human body fluids, indicating a good tolerance in
humans; therefore, exosomes carrying drugs could ex-
hibit a relatively long circulating half-life in vivo and
thus demonstrate improved efficacy. 3) Exosomes can
pass through the cell membrane and deliver carried sub-
stances to target cells; for example, DC-derived exo-
somes can transfer MHC molecules to other DCs,
regulating the immune response. 4) Exosomes exhibit
unique directionality, and many studies indicate that the
targeting function of exosomes is related to the cell
source. 5) Exosomes can modify their membrane and
enhance their cell-specific targeting function; for ex-
ample, exosomes loaded with siRNA toward beta-
secretase 1 (BACE1) could cross the blood-brain barrier
and down-regulate mRNA and protein BACE1 expression
by 60 % in brain neurons, astrocytes and oligodendrocytes.
6) Different from traditional synthetic liposomes, exo-
somes can carry drugs both in vivo and in vitro; in vivo,
drugs can be loaded into cells by transfection to obtain
targeted exosomes; in vitro, drugs can be loaded into
purified exosomes by electroporation and lipid trans-
fection [99, 100].
In recent years, a number of studies have shown that
exosomes, as a natural source of nanoscale vesicles, can
transfer exogenous RNAs (including siRNAs and miRNAs)
by specifically targeting tissues or cells for the purpose of
silencing genes and suppressing tumor growth in mice
[101, 102]. Shtam et al. [103] revealed that siRNAs can be
successfully transferred to targeted cells by means of exo-
somes for the purpose of gene therapy.
In addition, exosomes may also mediate mRNA/pro-
tein transfer among cells and could potentially be used
to deliver therapeutic genes to tumor cells, replace dys-
functional genes, and induce either an immune response
or tumor cell apoptosis [104]. Mizrak et al. [105] found
that after exosomes enriched with cytosine deaminase-
uracil phosphoribosyltransferase (CD-UPRT) mRNA/
protein were injected into murine nerve sheath tumors,
the exosomes could release encapsulated CD-UPRT
mRNA/protein into the target cells. These exosomes co-
ordinated with 5-fluorocytosine (5-FC) to treat murine
schwannoma and could promote the transformation of
5-FC into 5-fluorodeoxyuridine monophosphate, signifi-
cantly inducing tumor cell apoptosis and tumor regres-
sion. On the other hand, in the process of inducing bone
marrow cell differentiation into DCs, cells were co-cultured
overnight with ovalbumin (OVA) and α-galactose (αGC);
the extracted exosomes were enriched with the protein and
glycolipid antigens. Further results showed that exosomes
loaded with αGC-OVA could activate invariant NK cells,
overcome the effect of αGC, and enhance the tumor-
specific adaptive immune response; these findings support
the development of novel cancer immunotherapies [106]. A
phase I clinical trial showed that exosomes extracted from
heat-treated carcinoembryonic antigen (CEA) + tumor-de-
rived LS-174 T cells were enriched in CEA, HSP70 and
MHC I. Then, the exosomes were co-cultured with mono-
nuclear cells that were extracted from the serum of CEA+
patients, and the resulting sensitized DCs were injected into
patients to induce a strong CEA-specific T cell anti-tumor
effect. The test results showed that 60 % of patients had a
CEA-specific T cell response and that the treatment was
well tolerated; however, the immunostimulation was limited
and requires further optimization [107].
Exosomes can also be loaded with other types of mate-
rials, e.g., chemotherapy drugs, for therapeutic applica-
tions. Recent studies have found that imDC-derived
exosomes can be modified by iRGD and electroporation
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to carry doxorubicin. These exosomes can target αv in-
tegrin via the co-expression of Lamp2b, which can even-
tually lead to the directional transfer of doxorubicin into
breast cancer MDA-MB-231 cells, MCF-7 cells, murine
melanoma B16-F10 cells and human HCC cells, e.g.,
HepG2, as these cells have high αv integrin expression
levels [108]. Due to its low bioavailability and poor sta-
bility, the application of curcumin in cancer and other
inflammatory diseases is limited; however, exosomes can
improve the stability of this natural medicinal compound
[109]. Studies have shown that via co-incubation, curcu-
min can self-assemble into the lipid bilayer of exosomes
and thereby escape degradation, resulting in improved
stability and bioavailability [110]. Recently, Hood et al.
[111] found that replacing phosphate-buffered saline
with trehalose pulse media during electroporation can
enable the successful loading of exosomes with heavier
cargo, such as superparamagnetic iron oxide nanoparti-
cles. This work not only achieved the loading of exo-
somes with semi-synthetic nanoparticles but also
highlighted the diagnostic potential of exosomes in mag-
netic resonance imaging [112].
Exosomes in anti-tumor vaccines
Aside from loaded exosomes, unloaded tumor cell-
derived exosomes can also be effective as prophylactic
and therapeutic anti-cancer vaccines, and such vaccines
have produced good anti-tumor effects in murine tumor
models. Mice immunized with tumor cell-derived exo-
somes exhibited a tumor formation rate that was
significantly lower than that of mice immunized with
tumor cell lysates [113]. Numerous studies have shown
that tumor cell-derived exosomes carrying large quan-
tities of tumor-specific antigens can induce DCs to re-
lease exosomes. Such exosomes can be loaded with
tumor-specific antigens, e.g., costimulatory molecules, to
induce an anti-tumor immune response [114]. A previ-
ous clinical trail has confirmed the safety of this tumor
immunotherapy. Morse et al. [115] demonstrated that
the condition of some non-small-cell lung cancer pa-
tients stabilized after treatment with exosomes loaded
with melanoma antigens. Research on liver cancer cell-
derived exosomes has shown that exosomes carrying
heat shock proteins can enhance tumor immunogenicity
and the immune response of induced NK cells, which
provides valuable clues for the development of efficient
liver cancer vaccines.
Specific removal of exosomes
Since tumor-derived exosomes play an important role in
tumor development, blocking the highly efficient secre-
tion of these exosomes, intercepting exosomes that are
secreted into the peripheral circulation, and inhibiting
the absorption of exosomes by recipient cells are potential
exosome-specific therapeutic strategies [116]. Aethlon
Medical specially designed a dialysis method called
Aethlon ADAPTTM, which uses antibodies and affinity re-
agents to achieve the specific removal of tumor cell-
derived exosomes [117].
Fig. 3 Underlying mechanisms by which exosomes induce formation, growth, metastasis, resistance in development of cancer
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Conclusions and propects
In recent years, the rapid development of the exosome
field has attracted the attention of many scientists and
clinicians. As a newly discovered means of intercellular
information transfer, exosomes play an important role in
tumorigenesis (Fig. 3) and have attractive prospects for
application in the early diagnosis and treatment of
tumors as well as in the assessment of prognoses. How-
ever, exosome research is still in an early stage, and
many problems, such as the following examples, require
further exploration before they can be resolved. 1) Con-
firming the contents of exosomes is critical for the safe
production and effective synthesis of exosomes. How-
ever, there is still a lack of not only accurate and versa-
tile methods for characterizing exosomes but also rapid,
economical, efficient and standardized separation tech-
nologies; furthermore, there is a lack of information
regarding the differences in the formation mechanisms,
components and functions of exosomes in different con-
ditions. 2) Exosomes can be used as a delivery system
based on their unique characteristics, and they are su-
perior to artificial carriers in many ways. However, con-
sidering the potential administration routes, dosages,
and costs, the design principles for loaded exosome-
based therapies require further improvement. 3) The
regulation of mRNAs by exosomes enriched with tumor-
promoting miRNAs is not fully understood. In addition,
whether recipient cells exhibit selectivity when exosomes
deliver functional proteins and RNAs remains to be de-
termined. Clarifying and resolving these scientific issues
and technical barriers may provide significant insights
into the unique biological structures and functions of
exosomes. In addition to influencing the development of
future drug carriers, such insights could provide not
only safe and convenient biomarkers for the early diag-
nosis of cancer but also targeted treatment strategies for
individual biological therapies.
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